Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
SARS-CoV2 infection in patients with comorbidities, particularly T2DM, has been a major challenge globally and has been shown to be associated with high morbidity and mortality. Here, we did whole blood immunophenotyping along with plasma cytokine, chemokine, antibody isotyping, and viral load from oropharyngeal swab to understand the immune pathology in the T2DM patients infected with SARS-CoV2.
Methods
Blood samples from 25 Covid-19 positive patients having T2DM, 10 Covid-19 positive patients not having T2DM, and 10 Covid-19 negative, non-diabetic healthy controls were assessed for various immune cells by analyzing for their signature surface proteins in mass cytometry. Circulating cytokines, chemokines, and antibody isotypes were determined from plasma while viral copy number was determined from oropharyngeal swabs. All our representative data corroborated with laboratory findings.
Results
Our observations encompass T2DM patients having elevated levels of both type I and type II cytokines and higher levels of circulating IgA, IgM, IgG1, and IgG2 as compared to NDM and healthy volunteers. They also displayed higher percentages of granulocytes, mDCs, plasmablasts, Th2-like cells, CD4 + EM cells, and CD8 + TE cells as compared to healthy volunteers. T2DM patients also displayed lower percentages of pDCs, lymphocytes, CD8 + TE cells, CD4 + , and CD8 + EM.
Conclusion
Our study demonstrated that patients with T2DM displayed higher inflammatory markers and a dysregulated anti-viral and anti-inflammatory response when compared to NDM and healthy controls and the dysregulated immune response may be attributed to meta inflammation.
Article activity feed
-
-
SciScore for 10.1101/2021.12.03.21267282: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Recombinant DNA Sentences Resources The N gene was cloned into pBiEx vector and 10-fold serial dilutions of the plasmid were done to obtain the standard curve. pBiExsuggested: NoneSoftware and Algorithms Sentences Resources FCS files were then normalised with CyTOF software V.7 (Fluidigm) and then exported and analysed by FlowJo software V10.7 (BD Biosciences). FlowJosuggested: (FlowJo, RRID:SCR_008520)Statistics: Statistical analysis was performed using the GraphPad Prism software, version 8.0.1. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)R…
SciScore for 10.1101/2021.12.03.21267282: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Recombinant DNA Sentences Resources The N gene was cloned into pBiEx vector and 10-fold serial dilutions of the plasmid were done to obtain the standard curve. pBiExsuggested: NoneSoftware and Algorithms Sentences Resources FCS files were then normalised with CyTOF software V.7 (Fluidigm) and then exported and analysed by FlowJo software V10.7 (BD Biosciences). FlowJosuggested: (FlowJo, RRID:SCR_008520)Statistics: Statistical analysis was performed using the GraphPad Prism software, version 8.0.1. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:We understand that our study is not devoid of limitations such as a small sample size, absence of longitudinal study or follow up, but nevertheless it will help in understanding the vulnerability of these patients and subsequent planning of vaccine coverage in these patients or future vaccines booster dosages to them.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
